-
Mayzent Approved in Australia for Treatment of Secondary Progressive MS
Novartis’s Mayzent has become the first treatment approved by Australia’s Therapeutic Goods Administration (TGA) for the treatment of SPMS. Read more about it here.
Are you excited about this news?
Sorry, there were no replies found.
Log in to reply.